What should be included in Endocrinology notes for a Canadian medical student sitting for the MCCQE1 exam?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Comprehensive Endocrinology Notes for MCCQE1 Exam

1. DIABETES MELLITUS

Type 1 Diabetes

  • Autoimmune destruction of pancreatic beta cells leading to absolute insulin deficiency 1
  • Presents with polyuria, polydipsia, weight loss, and lethargy 2
  • Cannot be treated with metformin alone - requires insulin therapy 1
  • Risk of diabetic ketoacidosis (DKA) with high ketones in blood/urine 1

Type 2 Diabetes

  • Insulin resistance with relative insulin deficiency 1
  • Metformin is first-line: decreases hepatic glucose production, decreases intestinal glucose absorption, improves peripheral insulin sensitivity 1
  • Metformin dosing: Start 500 mg once or twice daily with meals, titrate by 500 mg weekly up to maximum 2550 mg/day 1
  • Metformin reduces FPG by ~53 mg/dL and HbA1c by ~1.4% 1
  • Contraindications to metformin: kidney disease, liver disease, heart failure, age >80 without kidney function testing, alcohol abuse 1

Diabetic Emergencies

Diabetic Ketoacidosis (DKA)

  • Hyperglycemia, ketosis, metabolic acidosis 3
  • Management: IV fluids, insulin therapy, electrolyte replacement, treat precipitating factors 3
  • Check urine/blood ketones, acid-base status, electrolytes immediately 2

Hyperosmolar Hyperglycemic State (HHS)

  • Severe hyperglycemia, hyperosmolality, dehydration without significant ketosis 3
  • Management: aggressive fluid resuscitation, insulin, electrolyte replacement 3

Severe Hypoglycemia

  • Blood glucose <54 mg/dL with neurological symptoms 3
  • Management: IV glucose (D50W) for unconscious patients, glucagon if no IV access 3

2. THYROID DISORDERS

Hypothyroidism

Primary Hypothyroidism

  • Elevated TSH with low free T4 2
  • Levothyroxine dosing for patients <70 years without cardiac disease: ~1.6 mcg/kg/day based on ideal body weight 2
  • For patients >70 years or with cardiac disease/frailty: start 25-50 mcg daily and titrate up 2
  • Monitor TSH every 4-6 weeks during titration 2
  • Overtreatment indicated by low TSH - reduce or discontinue dose 2

Central (Secondary) Hypothyroidism

  • Low TSH with low free T4 - indicates pituitary/hypothalamic dysfunction 2
  • Goal free T4 in upper half of reference range (TSH not accurate for monitoring) 2
  • Evaluate for hypophysitis 2

Hyperthyroidism/Thyrotoxicosis

Thyroiditis (Most Common with Immune Checkpoint Inhibitors)

  • Low TSH with elevated free T4 2
  • Grade 1 (mild): Beta-blocker (atenolol or propranolol) for symptoms, monitor thyroid function every 2-3 weeks 2
  • Grade 2 (moderate): Consider holding treatment, beta-blocker, hydration, endocrine consultation 2
  • Grade 3-4 (severe): Hold treatment, hospitalize, beta-blocker, consider steroids/SSKI/thionamides 2
  • Usually self-limited, resolves in weeks, often progresses to hypothyroidism 2

Graves' Disease

  • Persistent thyrotoxicosis with TSH receptor antibodies 2
  • Physical exam: ophthalmopathy, thyroid bruit 2
  • Treatment: antithyroid drugs (methimazole/propylthiouracil), radioactive iodine, or surgery 2

Thyroid Storm

  • Life-threatening severe thyrotoxicosis with multi-organ dysfunction 3
  • Management: beta-blockers, thionamides, hydration, supportive care 3

Myxedema Coma

  • Life-threatening severe hypothyroidism with altered mental status and hypothermia 3
  • Management: ventilatory support if needed, careful fluid management, treat precipitating factors 3

3. ADRENAL DISORDERS

Primary Adrenal Insufficiency

Diagnosis

  • AM cortisol <3 mg/dL with elevated ACTH (>2-3× ULN) 2
  • Check basic metabolic panel (Na, K, CO2, glucose), renin, aldosterone 2
  • ACTH stimulation test if AM cortisol 3-15 mg/dL 2
  • Adrenal CT for metastasis or hemorrhage 2

Management

  • Grade 1 (mild): Hydrocortisone 15-20 mg daily in divided doses (2/3 morning, 1/3 early afternoon) 2
  • Grade 2 (moderate): Oral pulse dose therapy, clinic evaluation for volume repletion 2
  • Grade 3-4 (severe): Hold treatment, hospitalize, IV stress-dose steroids 2
  • All patients need: stress dosing education, emergency injectable, medical alert bracelet 2

Adrenal Crisis

Presentation

  • Severe hypotension (refractory to fluids), shock, electrolyte abnormalities 3
  • Fever, altered mental status, hyponatremia, hyperkalemia 3
  • Triggers: infections, surgery, injuries, severe allergic reactions 3

Management

  • Immediate hydrocortisone 100 mg IV bolus 3
  • Followed by 100-300 mg/day as continuous infusion or divided every 6-8 hours 3
  • Rapid IV isotonic saline (0.9%) at 1 L/hour initially 3
  • Evaluate for precipitating cause 2

Secondary (Central) Adrenal Insufficiency

  • Low ACTH with low cortisol 2
  • Manage as hypophysitis (see below) 2
  • No aldosterone deficiency (renin-angiotensin system intact) 2

4. PITUITARY DISORDERS

Hypophysitis

Diagnosis

  • Low TSH with low free T4 suggests central hypothyroidism 2
  • Check AM ACTH, cortisol, TSH, free T4, LH, FSH, testosterone/estrogen 2, 3
  • MRI brain with pituitary cuts: shows pituitary enlargement, stalk thickening, suprasellar convexity 2
  • Most common: central hypothyroidism (>90%), central adrenal insufficiency (>75%), panhypopituitarism (50%) 2

Management

  • All grades: Endocrine consultation, stress dosing education, medical alert bracelet 2
  • Grade 1: Consider holding treatment, corticosteroid replacement (hydrocortisone 15-20 mg divided), thyroid hormone replacement, sex hormone replacement if needed 2
  • Grade 2: Consider holding treatment, clinic evaluation, oral pulse dose steroids 2
  • Grade 3-4: Hold treatment, hospitalize, IV stress-dose steroids 2
  • Critical: Initiate adrenal replacement before thyroid replacement to avoid precipitating adrenal crisis 2

Pituitary Apoplexy

  • Acute hemorrhage/infarction of pituitary tumor 3
  • Sudden headache, visual disturbances, hormonal deficiencies 3
  • Management: immediate high-dose glucocorticoids, neurosurgical evaluation for decompression, hormone replacement 3

5. CALCIUM DISORDERS

Hypocalcemia

In 22q11.2 Deletion Syndrome Context

  • Occurs in ~60% of children with 22q11.2DS 2
  • May present as transient neonatal hypocalcemia or hypocalcemic seizures 2
  • Can recur during stress: perioperative, acute illness, puberty, pregnancy, decreased oral intake 2
  • Symptoms: fatigue, irritability, seizures, paresthesias, muscle cramps, tremors, rigidity 2

Severe Hypocalcemia

  • Serum calcium <7.5 mg/dL or symptomatic 3
  • Management: IV calcium gluconate for severe symptoms, vitamin D supplementation, treat underlying cause 3

Hypercalcemia

Severe Hypercalcemia

  • Serum calcium >14 mg/dL or symptomatic 3
  • Management: aggressive IV fluid resuscitation, bisphosphonates, calcitonin, treat underlying cause 3

6. PARATHYROID DISORDERS

Hypoparathyroidism

  • Most common endocrine issue in 22q11.2DS 2
  • Monitor with TSH and free T4 every 1-2 years 2
  • Can be complete or partial 2

7. GROWTH DISORDERS

Growth Hormone Deficiency

  • Rare but responds well to growth hormone therapy when present 2
  • Growth restriction pattern: early deceleration of weight/stature, weight recovery with less stature catch-up 2
  • Mean height at age 19: females and -0.72 SD for males 2
  • Measure height/weight regularly, consider parental height 2

8. REPRODUCTIVE ENDOCRINOLOGY

Hypogonadism

  • Evaluate LH, testosterone in males; FSH, estrogen in premenopausal females with fatigue, loss of libido, mood changes, oligomenorrhea 2
  • Testosterone or estrogen therapy if needed in those without contraindications (prostate cancer, breast cancer, DVT history) 2

Pubertal Development

  • Hormones orchestrate sexual development, sexuality, reproduction through life history transitions, contextual responses, cyclical patterns 4

9. IMMUNE CHECKPOINT INHIBITOR-RELATED ENDOCRINOPATHIES

General Principles

  • Endocrine dysfunction can be managed with hormone replacement - may not require stopping immunotherapy 2
  • Organ failure managed with replacement rather than immunosuppression 2
  • High-dose corticosteroids have not shown benefit for pituitary hormone recovery 2

Checkpoint Inhibitor-Associated Diabetes Mellitus (CIADM)

  • Autoimmune pathophysiology similar to type 1 diabetes 2
  • New-onset hyperglycemia without type 2 diabetes risk factors should raise concern 2
  • Acute onset: polyuria, polydipsia, weight loss, lethargy 2
  • Check urine ketones, acid-base status, electrolytes for DKA screening 2
  • Send antibodies, insulin, C-peptide but don't delay treatment 2
  • Treat with insulin - no immunosuppressive strategies approved 2
  • Endocrinology consultation appropriate; hospitalize if outpatient consultation unavailable 2

10. PERIOPERATIVE ENDOCRINE MANAGEMENT

Stress-Dose Steroids for Surgery

  • Patients with adrenal insufficiency: Hydrocortisone 100 mg IV at surgery start, followed by 200 mg/24 hours infusion 3
  • Endocrine consultation before surgery or high-stress treatments 2

11. MONITORING AND LABORATORY INTERPRETATION

Routine Monitoring

  • Before starting immune checkpoint inhibitors: TSH, free T4, AM ACTH, cortisol, glucose, HbA1c 2
  • Before each cycle: TSH, free T4, basic metabolic panel 2
  • Consider monthly for 6 months, then every 3 months for 6 months, then every 6 months for 1 year: AM ACTH and cortisol 2

Pre-analytical Considerations

  • Patient history, clinical assessment, and laboratory investigations form diagnostic basis 5
  • Pre-analytical and analytical variability affects clinical significance 5

12. ENDOCRINE SYSTEM OVERVIEW

Hormonal Regulation

  • Hypothalamus produces releasing/inhibiting hormones acting on pituitary 6
  • Pituitary hormones act on target glands (adrenal, gonads, thyroid) or directly on target organs 6
  • Regulatory cascades: hypothalamic hormone → pituitary hormone(s) → target gland hormone(s) 6

Major Endocrine Glands

  • Adrenal glands: primarily cortisol 6
  • Gonads (ovaries/testes): sex hormones 6
  • Thyroid: thyroid hormone 6
  • Parathyroid: parathyroid hormone 6
  • Pancreas: insulin and glucagon 6

13. SPECIAL POPULATIONS

Children (Ages 10-16)

  • Metformin effectively lowers glucose in children with type 2 diabetes 1
  • Not studied in children <10 years 1
  • Not studied in combination with other oral agents or insulin in children 1

Pregnancy

  • Unknown if metformin harms unborn baby - discuss best blood sugar control options 1
  • Hypocalcemia can recur during pregnancy in those with hypoparathyroidism 2

Breastfeeding

  • Unknown if metformin passes into breast milk - discuss feeding options 1

14. KEY CLINICAL PITFALLS

Thyroid

  • Elevated TSH in recovery phase of thyroiditis - monitor asymptomatic patients with normal free T4 for 3-4 weeks before treating 2
  • TSH not accurate in central hypothyroidism - use free T4 for monitoring 2

Adrenal

  • Distinguish primary vs secondary adrenal insufficiency by ACTH-cortisol relationship 2
  • Always replace adrenal hormones before thyroid hormones to avoid precipitating adrenal crisis 2

Diabetes

  • New hyperglycemia without type 2 risk factors - consider CIADM and check for DKA 2
  • Metformin contraindicated in kidney disease, liver disease, heart failure 1

Calcium

  • Hypocalcemia can recur during biologic stress even after initial resolution 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Endocrine Emergency Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The endocrine system: an overview.

Alcohol health and research world, 1998

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.